Acorda Therapeutics announced the submission of new regulatory filings for the approval of Inbrija in six countries in Latin America by its partner Biopas Laboratories. Inbrija is indicated in the United States for the intermittent treatment of OFF episodes in adult patients with Parkinson’s disease, or PD, treated with carbidopa/levodopa. Biopas has submitted for marketing approval of Inbrija in Argentina, Colombia, Costa Rica, Ecuador, Panama and Peru. It expects to submit additional regulatory filings for approval of Inbrija in Chile in late 2023 and in Mexico and Brazil in 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue